PDSinh-C01
PDSinh-C01 is a reversible, non-competitive pendrin (SLC26A4) inhibitor with an IC50 of 2.5 μM. PDSinh-C01 inhibits pendrin-mediated Cl−/SCN− exchange activity, reduces cell counts, protein levels, and pro-inflammatory cytokine production in bronchoalveolar lavage fluid. PDSinh-C01 can be used in research related to acute lung injury and cystic fibrosis.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 2128304-65-2
- 화학식: C20H23N3O2S2
- 분자량:401.55
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- 순도&문서
- References
-
Help & FAQs
Biological Activity
제품 설명
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:LPS-stimulated HPAEpiC
-
Concentration:20 μM
-
Incubation Time:1 h (pre-incubation prior to 24 h LPS stimulation)
-
Result:Significantly reduced LPS-increased pendrin/β-actin and phospho-IκB/total IκB ratios to levels comparable to vehicle control.
In Vivo
PDSinh-C01 (10 mg/kg; i.p.; administered twice) alleviates LPS-induced acute lung injury in male C57BL/6J mice and reduces key inflammatory and injury markers[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, 8 weeks old, 20-25 g, intranasal instillation of 10 mg/kg LPS)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; single dose 1 hour prior to LPS exposure
-
Result:Significantly reduced LPS-induced increases in BALF total cell counts, protein concentration, and neutrophil counts compared to the LPS-only group.
Significantly reduced lung injury scores, pendrin protein expression, phospho-IκB protein expression, pendrin mRNA levels, and lung tissue levels of pro-inflammatory cytokines IL-1β, MIP-2, IL-6, and TNF-α compared to the LPS-only group.
Showed significantly higher lung injury scores than in the YS-01-treated pre-treatment group.
-
Animal Model:C57BL/6J (male, 8 weeks old, 20-25 g, intranasal instillation of 10 mg/kg LPS)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; two doses at 6 and 12 hours after LPS exposure
-
Result:Significantly reduced LPS-induced increases in BALF total cell counts, protein concentration, neutrophil counts, and macrophage counts compared to the LPS-only group.
Significantly reduced lung injury scores (with scores significantly lower than in the YS-01-treated post-treatment group), pendrin protein expression, phospho-IκB protein expression, pendrin mRNA levels, and lung tissue levels of pro-inflammatory cytokines IL-1β, MIP-2, IL-6, and TNF-α compared to the LPS-only group.
Chemical Information
-
CAS No. 2128304-65-2
-
분자량 401.55
-
화학식 C20H23N3O2S2
-
SMILES
CC1=NNC(C2=CC(S(NC3C(C=CC=C4)=C4CCC3)(=O)=O)=C(C)S2)=C1C
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
[1]. Choi HK, et al. The comparison of two pendrin inhibitors, YS-01 and PDSinh-C01, in lipopolysaccharide-induced acute lung injury. Scientific reports. 2026 Jun 23. [Content Brief]
[2]. Lipani A, et al. Modulators of anion channels and transporters as alternative therapeutic agents to normalize airway surface liquid in cystic fibrosis. European journal of medicinal chemistry. 2026 Jan 15;302(Pt 2):118325. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PDSinh-C01 Related Classifications
HY-184898 Related Classifications
Powered by Bioz